The US FDA has accepted an amended investigational new drug application for the production and distribution of Radiopharm Theranostics' 68Ga-Trivehexin (RAD 301).
US FDA gives green light for Trivehexin diagnostic Phase 1 pancreatic clinical trial
October 18, 2023 Australian Biotech
Latest Video
New Stories
-
Merck expands commitment to first nations STEM leadership with new scholarships and partnerships
October 19, 2025 - - Latest News -
Orthocell boosts balance sheet with capital raise to drive nerve repair product growth
October 19, 2025 - - Australian Biotech -
Amplia targets US market expansion as FAK inhibitor shows promise in pancreatic cancer
October 19, 2025 - - Australian Biotech -
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 - - Latest News -
AdvanCell unveils promising first clinical results for 212Pb-ADVC001 in prostate cancer
October 19, 2025 - - Australian Biotech -
Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access
October 18, 2025 - - Latest News -
An exceptional outcome that must not become an exception
October 18, 2025 - - Latest News